News | April 12, 2022
Wacker, CordenPharma to produce mRNA vaccines for Germany
Both companies have been selected for stand-by production by German government
Both companies have been selected for stand-by production by German government
All intellectual-property disputes related to the market entry of Alvotech’s AVT02 (adalimumab) in the U.S. and Europe are now resolved
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales)
The launch of medical cannabis products resulted from an agreement between the two companies signed in 2021
Evusheld significantly reduced the risk of developing symptomatic COVID-19 in PROVENT Phase III trial, with protection lasting at least six months
This targeted capacity-building and advocacy project in 15 districts and 5 states of India has facilitated the certification of disability for 11,152 people, provided disability pensions to 8,144 people and supported the issuing of voter IDs to 8,450 people with disabilities
Recommendation based on Phase III PROVENT trial showing a significant reduction in the risk of developing symptomatic COVID-19, with protection lasting at least six months
The announcement follows recent authorization of the Company's mRNA COVID-19 vaccine in Australia and the European Union for children aged 6-11 years
Data from this study will support a submission to expand the use of atogepant to include preventive treatment of chronic migraine in the United States and additional submissions globally
Clinical trial supply company strengthens its presence in the European Union
Subscribe To Our Newsletter & Stay Updated
